OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (OSIREAL)

An Ambispective, Non-interventional, Multiple Cohort Study to Assess the Management of Osimertinib Treatment in Patients With EGFRm Non-small Cell Lung Cancer Under Real-world Conditions in Spain

Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers.

Osimertinib is indicated as monotherapy for the first-line (1L) treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations in the EGFR, for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC, for the adjuvant treatment of adult patients with NSCLC stages IB-IIIA after complete resection of the tumor that has activating mutations of the EGFR, for the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutation and whose disease has not progressed during or following platinum-based chemoradiation therapy, and in combination with pemetrexed and platinum-based chemotherapy for the 1L treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations.

The FLAURA trial showed that treatment with osimertinib significantly prolongs PFS and improves overall survival (OS) compared to standard EGFR tyrosine kinase inhibitors.

The results of the ADAURA study showed a reduction in the risk of recurrence or death by 83% in stages II to IIIA, and in 80% in stages IB-IIIA. Additionally, osimertinib demonstrated a highly statistically significant improvement in DFS and HRQoL was maintained.

The FLAURA2 trial showed that 1L treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR mutated (EGFRm) advanced NSCLC.

The LAURA trial showed that treatment with osimertinib after chemoradiotherapy resulted in significantly longer PFS than placebo among patients with unresectable stage III EGFRm NSCLC.

To date, there are no real-world data on osimertinib either in 1L treatment in locally advanced or metastatic EGFRm NSCLC nor as adjuvant treatment, in early stages of cancer, regarding effectiveness, adherence, treatment exposure and quality of life (QoL), among others, and in particular for the use of osimertinib in subpopulations less represented in pivotal trials such as elderly or patients with uncommon EGFR mutations. Furthermore, the duration of treatment in real life in Spain is also a gap, as it appears to be longer than in clinical trials, which means that there are patients who are treated beyond progression.

Therefore, this observational ambispective study based on real-world data aims to provide data on osimertinib use as adjuvant treatment in adult patients diagnosed with stages IB-IIIA EGFRm NSCLC, in 1L treatment in patients with locally advanced or metastatic EGFRm NSCLC, as consolidation treatment in patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy, and in combination with pemetrexed and platinum-based chemotherapy in patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution. Specifically, the study will focus on patient characteristics, adherence, treatment exposure, administration, survival, quality of life, effectiveness and safety providing insights into osimertinib use in daily practice for patients with EGFRm NSCLC, where there are current evidence gaps.

Study Overview

• Status: Recruiting
• Conditions: Non-small Cell Lung Cancer

Detailed Description

Cancer continues to be one of the leading causes of morbidity and mortality in the world. It is estimated that in the year 2020, approximately 18.1 million new cases of cancer in the world, and that this figure will increase in the next two decades to 27 million. The most frequently diagnosed tumors in the world in 2020 were those of the breast, lung (which occupies the second position), colon and rectum, prostate and stomach, all of them with more than one million cases.

Also, in Spain, cancer is one of the main causes of morbidity and mortality. It is estimated that in 2020 there were 113,054 deaths from cancer in Spain. The number of cancers diagnosed in Spain in 2022 is estimated to reach 280,100 cases according to REDECAN calculations, which represents a slight increase compared to previous years. Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. After prostate cancer, it is the second most common cancer in men and, after breast cancer, in women. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers.

The most frequently diagnosed cancers in Spain in 2023 will be those of the colon and rectum, breast, lung, prostate, and urinary bladder. Lung cancer is a very common cancer in Spain, however, due to its high mortality, its prevalence at five years is relatively low.

Approximately 30% of patients with non-small cell lung cancer (NSCLC) have early-stage disease that is treated with surgery. A high percentage of these patients relapse and die, so patients receive postoperative adjuvant systemic chemotherapy to increase their survival. However, the benefits of this strategy are modest. NSCLC is often associated with druggable molecular alterations that drive lung carcinogenesis. EGFR tyrosine kinase inhibitors (TKIs) have been included in treatment paradigms with the aim of improving the outcome of adjuvant therapy in patients with completely resected, EGFR mutation-positive (EGFRm+) disease.

Osimertinib is indicated as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR), for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC, for the adjuvant treatment of adult patients with NSCLC stages IB-IIIA after complete resection of the tumor that has activating mutations of the EGFR (exon 19 deletion or exon 21 substitution (L858R)), for the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy, and in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

The FLAURA trial showed that treatment with osimertinib significantly prolongs progression-free survival (PFS) compared to EGFR TKI comparator (median 18.9 months and 10.2 months, respectively, HR=0.46, 95% CI: 0.37, 0.57; P<0.0001) (5) and improves overall survival (OS) (HR=0.799 [95.05% CI: 0.641, 0.997]) compared to standard EGFR tyrosine kinase inhibitors (TKIs), in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). A greater proportion of patients treated with osimertinib were alive at 12, 18, 24 and 36 months (89%, 81%, 74% and 54% respectively) compared to patients treated with EGFR TKI comparator (83%, 71%, 59% and 44% respectively).

The results of the ADAURA trial showed that adjuvant treatment with osimertinib reduced the risk of recurrence or death by 83% in stages II to IIIA, and in 80% in stages IB-IIIA, compared with placebo, in patients with NSCLC with completely resected stage IB to IIIA disease and confirmed EGFR mutation. Additionally, osimertinib demonstrated a highly statistically significant improvement in disease free survival (DFS) and HRQoL was maintained. A DFS benefit favouring osimertinib over placebo was seen across all prespecified subgroups, including those based on disease stage, EGFR sensitizing mutation, ethnicity and receipt of adjuvant chemotherapy. Furthermore, the DFS benefit with osimertinib was similar in patients who had or had not received chemotherapy.

The FLAURA2 trial showed that first-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR mutated advanced NSCLC . Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib- chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. An objective response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.

The LAURA trial showed that treatment with osimertinib after chemoradiotherapy resulted in significantly longer progression-free survival than placebo among patients with unresectable stage III EGFR-mutated NSCLC. Osimertinib offered a median PFS of 39.1 months, compared with only 5.6 months with placebo (HR 0.16, 95% CI [0.10, 0.24]; P<0.0001). The percentage of patients who were alive and progression free at 12 months was 74% (95% CI, 65 to 80) with osimertinib and 22% (95% CI, 13 to 32) with placebo. The overall safety profile of osimertinib after chemoradiotherapy was consistent with the established profile of osimertinib and chemoradiotherapy.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: AstraZeneca Clinical Study Information Center; Phone Number: 1-877-240-9479; Email: information.center@astrazeneca.com

Study Locations

• Spain
  • A Coruña, Spain
    • Recruiting
    • Research Site
  • Alicante, Spain
    • Recruiting
    • Research Site
  • Barcelona, Spain
    • Recruiting
    • Research Site
  • C Rdoba, Spain
    • Recruiting
    • Research Site
  • El Palmar, Spain
    • Recruiting
    • Research Site
  • Girona, Spain
    • Recruiting
    • Research Site
  • Granada, Spain
    • Recruiting
    • Research Site
  • Jaén, Spain
    • Recruiting
    • Research Site
  • Las Palmas de Gran Canaria, Spain
    • Recruiting
    • Research Site
  • León, Spain
    • Recruiting
    • Research Site
  • Lleida, Spain
    • Recruiting
    • Research Site
  • Madrid, Spain
    • Recruiting
    • Research Site
  • Madrid, Spain
    • Withdrawn
    • Research Site
  • Málaga, Spain
    • Recruiting
    • Research Site
  • Ourense, Spain
    • Recruiting
    • Research Site
  • Palma, Spain
    • Recruiting
    • Research Site
  • Sabadell, Spain
    • Recruiting
    • Research Site
  • Salamanca, Spain
    • Recruiting
    • Research Site
  • Santa Cruz de Tenerife, Spain
    • Recruiting
    • Research Site
  • Santander, Spain
    • Active, not recruiting
    • Research Site
  • Santiago de Compostela, Spain
    • Recruiting
    • Research Site
  • Seville, Spain
    • Recruiting
    • Research Site
  • Valencia, Spain
    • Recruiting
    • Research Site
  • Valladolid, Spain
    • Recruiting
    • Research Site
  • Vigo, Spain
    • Recruiting
    • Research Site
  • Zaragoza, Spain
    • Recruiting
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study population will include all adult EGFRm NSCLC patients receiving osimertinib according to SmPC.

Description

Inclusion Criteria:

• Female or male patients, treated with osimertinib
• Age ≥ 18 years at starts of osimertinib treatment (i.e., index date).

• Patients histologically diagnosed with EGFRm NSCLC (before index date):

  • Patients with first-line treatment with EGFRm locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy (Cohort 1).
  • Patients with stage IB-IIIA whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, after complete tumor resection (Cohort 2).
  • Patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, that received osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment (Cohort 3).
  • Patients with locally advanced, unresectable NSCLC treated with osimertinib, whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy (cohort 4).
• Provision of informed consent (for alive patients). Deceased patients who met the selection criteria when they started treatment with osimertinib could also be included in the study.

Exclusion Criteria:

• Osimertinib treatment administration in a clinical trial setting.

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort
Cohort 1; Patients diagnosed with locally advanced or metastatic NSCLC with activating EGFR mutations that received first line treatment with osimertinib (FLAURA regimen).
Cohort 2; Patients with stage IB-IIIA NSCLC after complete tumour resection that has activating mutations in the EGFR (deletion of exon 19 or substitution of exon 21 [L858R]) that received adjuvant treatment with osimertinib (ADAURA regimen).
Cohort 3; Patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, that received osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first- line treatment (FLAURA2 regimen).
Cohort 4; Patients with locally advanced, unresectable NSCLC treated with osimertinib, whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy (LAURA regimen).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the effectiveness of osimertinib in terms of median OS in patients with locally advanced or metastatic EGFRm NSCLC (Cohort 1).	- Overall survival (OS) measured as median time from start of osimertinib treatment to death. The primary measure of interest is median OS and corresponding 95% confidence interval.	From start of osimertinib treatment to death, assessed up to 6 years
To evaluate the effectiveness of osimertinib in terms of 4-year rwDFS rate in patients with stages IB-IIIA EGFRm NSCLC (Cohort 2).	The primary measure of interest is the 4-year real world disease-free survival rate and corresponding 95% confidence interval. - 4-year real world disease-free survival rate for Cohort 2. (i.e., percentage of patients with clinical or radiological recurrence or death from any cause in the absence of disease recurrence 4 years after the start of osimertinib treatment, as evaluated by the treating physician according to standard clinical practice).	From start of osimertinib treatment to death, assessed up to 4 years.
To evaluate the effectiveness of osimertinib in combination with pemetrexed and platinum-based chemotherapy in terms of 3-year OS in adult patients with advanced NSCLC whose tumours have EGFRm exon 19 deletions or exon 21 (L858R) substitution (Cohort 3).	The primary measure of interest is 3-year overall survival rate and corresponding 95% confidence interval. - 3-year OS rate for Cohort 3 (i.e., percentage of patients alive 3 years after the start of osimertinib treatment).	From start of osimertinib treatment to death, assessed up to 3 years.
To evaluate the effectiveness of osimertinib (median rwPFS) in patients with locally advanced, unresectable NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations whose disease is stable during or after platinum-based CRT (Cohort 4).	- Real World Progression-free survival (rwPFS) defined as the median time from start of osimertinib treatment to clinical/radiological progression or death from any cause, in the absence of progression, as evaluated by the treating physician according to standard clinical practice. The primary measure of interest is median rwPFS and corresponding 95% confidence interval.	From start of osimertinib treatment to death, assessed up to 3 years.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To further evaluate the effectiveness of osimertinib in terms of rwPFS in patients with locally advanced or metastatic EGFRm NSCLC (Cohort 1).	Real World Progression-Free Survival (rwPFS) defined as the time from start of osimertinib treatment to clinical/radiological progression or death from any cause, in the basence of progression, as evaluated by the treating physician according to standard clinical practice. The measure of interest is the median rwPFS.	From start of osimertinib to clinical/radiological progression or death from any cause, whichever came first, assesed up to 6 years
To further evaluate the effectiveness of osimertinib in terms of rwDFS rates and OS in patients with stages IB-IIIA EGFRm NSCLC (Cohort 2).	The measure of interest is the median rwDFS and rates and corresponding 95% confidence intervals. Overall survival (OS) measured as median time from start of osimertinib treatment to death. The measure of interest is the median and OS rates and corresponding 95% confidence intervals.	From start of osimertinib to clinical/radiological recurrence or death from any cause, whichever came first, assesed up to 4 years
To further evaluate the effectiveness of osimertinib in combination with pemetrexed and platinum-based CT in terms of rwPFS and OS, in patients with advanced NSCLC whose tumours have EGFRm exon 19 deletions or exon 21 (L858R) substitution (Cohort 3).	The measure of interest is the 3-year rwPFS defined as percentage of patients with clinical or radiological progression or death from any cause in the absence of disease recurrence 3 years after the start of osimertinib treatment, as evaluated by the treating physician according to standard clinical practice. The measure of interest are OS rates and corresponding 95% confidence intervals.	From start of osimertinib to clinical/radiological progression or death from any cause, whichever came first, assesed up to 3 years.
To further evaluate the effectiveness of osimertinib in terms of CNS PFS, rwTTDM and 3-year OS (Cohort 4).	CNS PFS defined as the time to the earliest of CNS progression or death. rwTTDM defined as the time from osimertinib start date until the first date of distant metastasis or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the radiation field. The measures of interest are CNS PFS, rwTTDM and OS rate at 3 years and corresponding 95% confidence interval.	From start of osimertinib to clinical/radiological progression or death from any cause, whichever came first, assessed up to 3 years.
To describe the characteristics of osimertinib treatment administration for EGFRm NSCLC.	- Duration of treatment in real life, measured as time from start of osimertinib treatment to discontinuation of treatment or death from any cause in the absence of discontinuation (TTD). The measure of interest is discontinuation rates. - Real World Time to First Subsequent Therapy defined as the time from treatment initiation until the start of subsequent therapy or death (rwTFST). The measure of interest is discontinuation rates. - Frequency of dose changes and/or interruptions or reductions and their reasons.	During osimertinib treatment, assessed up to 6 years in cohort 1 and up to 3 years in cohorts 2, 3 & 4.
To describe healthcare resource use (HCRU) during the osimertinib treatment for EGFRm NSCLC in real life.	Healthcare resources used in relation to EGFRm NSCLC and its treatment assessed by the mean number of hospitalizations (and their duration) and outpatient, pharmacy and emergency unit visits related to EGFRm NSCLC and specific tests/procedures performed.	During osimertinib treatment, assessed up to 6 years in cohort 1 and up to 3 years in cohorts 2, 3 & 4.
To describe the safety profile of osimertinib in a real-world setting.	Events of clinical interest (ECIs) (start and end date, causality, impact on treatment (i.e., requires dose reduction or interruption), adverse events that lead to osimertinib dose changes, interruptions, or permanent discontinuation, and AEs that are considered serious (including fatal events).	During osimertinib treatment, assessed up to 6 years in cohort 1 and up to 3 years in cohorts 2, 3 & 4

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate patient reported outcomes and experience measures (PROMs and PREMs) in EGFRm NSCLC patients treated with Osimertinib as adjuvant treatment (only applicable to cohort 2).	Scores on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores on the SF-36: 36-Item Short Form Survey. The standard version of SF-36 has a recall period of four weeks. Scores on the treatment adherence questionnaire (ADAQ) will be reported weekly. Note: these questionnaires will only be collected for patients in cohort 2 who have initiated osimertinib treatment within a maximum period of 12 months before patient inclusion in the study.	SATMED-Q, SF-36: at study inclusion and every 6 months. ADAQ: at study inclusion and every week during on osimertinib treatment, an average of 3 years.
To evaluate PROMs and PREMs in patients with advanced NSCLC treated with osimertinib in combination with pemetrexed and platinum-based chemotherapy, whose tumours have EGFRm exon 19 deletions or exon 21 (L858R) substitution (Cohort 3).	Scores on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores on the SF-36: 36-Item Short Form Survey. The standard version of SF-36 has a recall period of four weeks. Scores on the treatment adherence questionnaire (ADAQ) will be reported weekly. Note: these questionnaires will only be collected for patients in cohort 3 who have initiated osimertinib treatment within a maximum period of 12 months before patient inclusion in the study.	SATMED-Q, SF-36: at study inclusion and every 6 months during osimertinib treatment, an average of 3 years. ADAQ: at study inclusion and every week during osimertinib treatment, an average of 3 years.
To describe the effectiveness, safety and use of healthcare resources of osimertinib monotherapy in patients with locally advanced or metastatic EGFRm NSCLC (Cohort 1) who have uncommon EGFR mutations.	rwPFS.; Overall survival.**Overall survival (OS) measured as median time from start of osimertinib treatment to death and rates.; AEs that lead to osimertinib dose changes, interruptions, or permanent discontinuation, ECIs during osimertinib treatment and AEs that are considered serious (including fatal events).; Healthcare resources used in relation to EGFRm NSCLC and its treatment.	rwPFS from start of treatment initiation until disease progression or death; OS from treatment initiation until death from any cause.
To describe the effectiveness, safety and use of healthcare resources of osimertinib monotherapy in elderly patients (>65 and >75 years) with locally advanced or metastatic EGFRm NSCLC (Cohorts 1, 3 & 4).	rwPFS.; Overall survival.; AEs that lead to osimertinib dose changes, interruptions, or permanent discontinuation, ECIs during osimertinib treatment and AEs that are considered serious, including fatal events.; Healthcare resources used in relation to EGFRm NSCLC and its treatment.	rwPFS from start of treatment initiation until disease progression or death; OS from treatment initiation until death from any cause.
To evaluate PROMs and PREMs in patients with locally advanced, unresectable NSCLC treated with osimertinib, with EGFR exon 19 deletions or exon 21 (L858R) mutations, whose disease is stable after platinum-based CRT (Cohort 4).	Scores on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores on the SF-36: 36-Item Short Form Survey. The standard version of SF-36 has a recall period of four weeks. Scores on the treatment adherence questionnaire (ADAQ) will be reported weekly. Note: these questionnaires will only be collected for patients in cohort 4 who have initiated osimertinib treatment within a maximum period of 12 months before patient inclusion in the study.	SATMED-Q, SF-36: at study inclusion and every 6 months during osimertinib treatment, an average of 3 years. ADAQ: at study inclusion and every week during osimertinib treatment, an average of 3 years.
To describe the adherence of patients with EGFRm NSCLC treated with osimertinib under real-world conditions (Cohorts 2, 3 & 4).	Adherence will be measured weekly using the Adelphi Adherence Questionnaire (ADAQ) through a mobile App managed by the company Naru Intelligence. Note: Only applicable to patients in cohorts 2, 3 and 4 who have started osimertinib treatment within a maximum period of 12 months before patient inclusion in the study.	ADAQ: reported at study inclusion and weekly thereafter during prospective follow-iup on osimertinib treatment, an average of 3 years.
To assess factors associated with outcomes among patients treated with osimertinib 1L (cohorts 1 & 3), and patients treated with osimertinib in the consolidation (cohort 4) or adjuvant setting (cohort 2).	Overall survival.; rwDFS; rwPFS; rwTTD; rwTFST; rw TTDM; CNS PFS Real World Time To Discontinuation (rwTTD) defined as the time from the start of osimertinib treatment to the end of the treatment. Real World Time to First Subsequent Therapy (rwTFST) defined as the time from treatment initiation until the start of subsequent therapy or death. Real Wolrd Time to Death or Distant Metastases (rwTTDM) defined as the time from the date of inclusion until the first date of distant metastasis or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the radiation field. CNS PFS defined as the time to the earliest of CNS progression or death.	rwTTD, rwTFST and CNS PFS from treatment initiation till end of treatment, start of subsequent theraypy/death or the earliest of CNS/progression, respectively. rwTTDM from date of inclusion till the first date of distant metastasis/death.
To describe the therapies received before and after osimertinib treatment progression or relapse.	Adjuvant, neoadjuvant: active drug, dose, mode of administration, duration, interruption.; Surgery: type, outcome (R0-R1).; Other treatments.; Therapies received after osimertinib treatment progression or relapse.	Before and after osimertinib treatment, assesed up to 6 years in cohort 1 and up to 3 years in cohorts 2, 3 & 4.

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Principal Investigator: Rosa Álvarez, Hospital General Universitario Gregorio Marañón; Principal Investigator: Delvys Rodriguez, Hospital Universitario Insular de Gran Canaria; Principal Investigator: Ana Cardeña, University Hospital of the Nuestra Señora de Candelaria; Principal Investigator: Martín Lázaro, Hospital Álvaro Cunqueiro; Principal Investigator: Luis Angel León Mateos, Complejo Hospitalario Universitario Santiago de Compostela; Principal Investigator: Rosario García, Hospital A Coruña; Principal Investigator: Ana Laura Ortega, Hospital Universitario Medico Quirúrgico Ciudad de Jaén; Principal Investigator: Silvia Sequero, Hospital Universitario San Cecilio; Principal Investigator: Angel Artal, Hospital Miguel Servet; Principal Investigator: Aitor Azkarate, Hospital Son Espases; Principal Investigator: Marta López-Brea, Hospital Universitario Marques de Valdecilla; Principal Investigator: Rafael López, Hospital Clinico Universitario de Valladolid; Principal Investigator: Soledad Medina, Hospital de Leon; Principal Investigator: Alberto Rodrigo, Hospital Universitario Arnau de Vilanova; Principal Investigator: Edurne Arriola, Hospital del Mar; Principal Investigator: Joaquim Bosch, Hospital Dr Josep Trueta (ICO Girona); Principal Investigator: Laia Vila, Corporación Parc Taulí; Principal Investigator: Jose Luis González Larriba, Hospital Universitario Clínico San Carlos; Principal Investigator: José Miguel Sánchez Torres, Hospital Universitario La Princesa; Principal Investigator: Silverio Ros, Hospital Clinico Universitario Virgen de la Arrixaca; Principal Investigator: Bartomeu Massuti, Hospital General Universitario de Alicante; Principal Investigator: Oscar Juan, Hospital Universitari i Politecnic La Fe de Valencia; Principal Investigator: Reyes Bernabé, Hospitales Universitarios Virgen del Rocío

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2023
• Primary Completion (Estimated): June 15, 2029
• Study Completion (Estimated): June 15, 2029

Study Registration Dates

• First Submitted: July 26, 2023
• First Submitted That Met QC Criteria: October 3, 2023
• First Posted (Actual): October 5, 2023

Study Record Updates

• Last Update Posted (Actual): May 27, 2026
• Last Update Submitted That Met QC Criteria: May 26, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung
• Other Study ID Numbers: D5162R00034

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org.
• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.